Sun Pharma has delivered a strong beat on FY23 earnings, led by broad-based growth across business segments.
We remain positive on Sun Pharma on the back of sustained scale-up in speciality portfolio, robust franchise building in branded generics portfolio, and healthy ANDA pipeline pending approvals Re-iterate BUY.
Glimpse the company's performance and key highlights to improve your decision.
📝 Read more: http://ow.ly/93NL50KZr3i🔗 Disclaimer: http://ow.ly/RK0h50KZrgj
⬇️ Download the app now: http://ow.ly/nKgB50KSKKk☑️ Follow us for such informative content.
🔖 Save the post for your future reference.
▶️ Share this post with your friends if you found it informative.
#MotilalOswal #CompanySpotlight #SunPharma #SunPharmastock #experttips #chooserightstocks #investmentadvice #stockmarket #stockrecommendations #stockratings #stockanalysis #fundamentalanalysis #technicalanalysis #technicalreserach #marketanalysis #expertadvice #MotilalOswal #CompanySpotlight #SunPharma #SunPharmastock #experttips #chooserightstocks #investmentadvice #stockmarket #stockrecommendations #stockratings #stockanalysis #fundamentalanalysis #technicalanalysis #technicalreserach #marketanalysis #expertadvice
Posted On: 03 Oct 2022 5:00 PM
